# Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs



# Gabriele Grunig<sup>1,2</sup>, Aram Baghdassarian<sup>1</sup>, Sung-Hyun Park<sup>1</sup>, Serhiy Pylawka<sup>3</sup>, Bertram Bleck<sup>2</sup>, Joan Reibman<sup>2</sup>, Erika Berman-Rosenzweig<sup>4</sup> and Nedim Durmus<sup>1</sup>

<sup>1</sup>Department of Environmental Medicine, New York University School of Medicine, New York, NY, USA. <sup>2</sup>Department of Medicine, New York University School of Medicine, New York, NY, USA. <sup>3</sup>College of Dental Medicine, Columbia University, New York, NY, USA. <sup>4</sup>Department of Pediatrics, School of Medicine, Columbia University, New York, NY, USA.

#### Supplementary Issue: Gene and Protein Expression Profiling in Disease

**ABSTRACT:** This review discusses biomarkers that are being researched for their usefulness to phenotype chronic inflammatory lung diseases that cause remodeling of the lung's architecture. The review focuses on asthma, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension. Biomarkers of environmental exposure and specific classes of biomarkers (noncoding RNA, metabolism, vitamin, coagulation, and microbiome related) are also discussed. Examples of biomarkers that are in clinical use, biomarkers that are under development, and biomarkers that are still in the research phase are discussed. We chose to present examples of the research in biomarker development by diseases, because asthma, COPD, and pulmonary hypertension are distinct entities, although they clearly share processes of inflammation and remodeling.

KEYWORDS: asthma, COPD, pulmonary hypertension, diagnosis, endotypes of disease, lung inflammation, lung remodeling

SUPPLEMENT: Gene and Protein Expression Profiling in Disease

**CITATION:** Grunig et al. Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs. *Biomarker Insights* 2015:10(S4) 59–72 doi: 10.4137/BMI.S29514.

TYPE: Review

RECEIVED: August 17, 2015. RESUBMITTED: October 14, 2015. ACCEPTED FOR PUBLICATION: October 18, 2015.

ACADEMIC EDITOR: Karen Pulford, Editor in Chief

PEER REVIEW: Six peer reviewers contributed to the peer review report. Reviewers' reports totaled 1309 words, excluding any confidential comments to the academic editor.

FUNDING: This work was funded by grants from the NIH (NHLBI 5 RO1 HL095764–04 [to GG]; NIEHS 1R03ES024797 [to S-HP]; NHLBI PVDOMICS [to EB-R]), TUBITAK (1059B191401602 to [ND]), and Hacettepe University (014 G 602 002 [to ND]). The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.

**COMPETING INTERESTS:** GG and SP are cofounders of Mirna Analytics LLC. JR reports grants from Novartis and Astra-Zeneca, outside the work presented here. Other authors disclose no potential conflicts of interest.

Introduction

Breathlessness, fatigue, insomnia, and cough are some of the signs of many chronic lung diseases. Together these symptoms lead to decreased quality of life. Some of these chronic lung diseases end in early mortality. Therefore, early detection, good prognostic measures, and personalized management of these diseases are highly desired.

Many chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), develop insidiously over many years and can remain undetected until large areas of the lungs are remodeled and have lost their structure.<sup>1,2</sup> Others, such as asthma, can be detected early on in childhood, but it is difficult to predict if the condition is going to resolve, persist, resolve and reappear, or persist in a progressively worsening clinical trajectory.<sup>3</sup> Still other conditions such as pulmonary hypertension are a challenge to correctly diagnose, because the breathlessness can be mistaken for a problem of airway function, instead of recognizing the increase in the pulmonary blood pressure.<sup>4,5</sup> CORRESPONDENCE: gabriele.grunig@nyumc.org, ggrunig1@earthlink.net COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

Paper subject to independent expert blind peer review. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to antiplagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).

Published by Libertas Academica. Learn more about this journal.

To date, most of the markers used for phenotyping in clinical use are either based on lung function, right heart function measurements, and imaging – particularly high-resolution X-ray computed tomography (CT) scans – or cellular analysis of bronchoalveolar lavage or sputum specimens (Table 1).<sup>6–16</sup> Molecular markers (Table 2),<sup>17–45</sup> while still limited, are being developed to facilitate detection of injury to cells within the lung structure and to identify molecular disease mechanisms in order to personally tailor therapeutic management. Additionally, biomarkers of disease risk and biomarkers that predict disease progression are being developed. The following sections discuss specific chronic conditions of the lungs with respect to the application of these different types of biomarkers.

#### **Biomarkers for Asthma**

Asthma affects approximately 300 million people worldwide (GINA guidelines 2015<sup>6</sup>). Asthma is a heterogeneous disease with a diagnosis dependent on the confluence of symptoms



Table 1. Examples of phenotyping procedures for asthma, COPD, or pulmonary hypertension.

PHENOTYPING PROCEDURE	STRUCTURE/SAMPLE BEING TESTED	INVOLVED PROCESS	INVOLVED DISEASE	CITATION
Lung function testing	Lung	Lung function	Asthma, COPD	7, 8
Response to broncho-dilators	Airways	Lung function	Asthma, COPD	9
Airway hyperreactivity	Airways	Lung function	Asthma	10
Right heart catheterization	Right heart	Heart function	Pulmonary hypertension	11
Exercise challenge	Right heart	Heart function	Pulmonary hypertension	11
Exhaled NO	Exhaled breath	Inflammation	COPD, asthma	7, 12, 13
Diffusing capacity for Carbon Monoxide (DLCO)	Exhaled breath	Lung function	COPD, pulmonary hypertension	12
High resolution CT	Lung	Lung remodeling	COPD, lung fibrosis, (pulmonary hypertension)	14
PET scan combined with CT	Lung	Abnormally active cells	COPD (pulmonary hypertension, asthma)	15
MRI scan	Right heart	Right heart morphology	Pulmonary hypertension (COPD)	11
Bronchoscopy, BAL	Airways	Inflammation, remodeling	COPD (asthma, pulmonary hypertension)	12
Induced sputum	Airways	Inflammation, remodeling	Asthma, COPD	16

Notes: Brackets indicate conditions for which certain assays/procedures are not commonly used, for example, bronchoscopy and BAL for asthma or pulmonary hypertension.

Abbreviations: BAL, bronchoalveolar lavage; CT, computed tomography; MRI, magnetic resonance imaging; NO, nitric oxide; PET, positron emission tomography.

and measurements of lung function showing variable airflow obstruction or airway hyperreactivity. Although the bronchi are the structures mainly affected in asthma, changes in small airways, bronchial blood vessels, and pulmonary blood vessels can also be present. Several biomarkers that characterize some of the phenotypes of asthma have included blood or sputum eosinophils, serum/plasma immunoglobulin E (IgE), and exhaled nitric oxide (NO).<sup>20</sup> An increase in the peripheral total IgE titer suggests the presence of an allergic response<sup>9,47</sup>; the allergic response can be further dissected by determining allergen-specific IgE or allergen-specific skin reactivity.

The challenge. The challenge is that asthma is heterogeneous and not all asthmatics are atopic (ie, have allergenspecific IgE). Moreover, some asthmatics fail to achieve control even with the use of high-dose therapy of bronchodilators and inhaled corticosteroids.<sup>17,48</sup> Additionally, current therapy is based on reducing symptoms and not curative; the symptoms of asthma return when the therapy is stopped.<sup>17</sup> The result is that bronchodilators and inhaled corticosteroids are often required for lifelong therapy, and these have the potential for significant side effects. Thus, new drugs are needed to modify pathways that are present in the different manifestations of asthma and that might reduce the need to use chronic corticosteroids.

Drugs that target specific inflammatory pathways have been sought after for years. The first leukotriene antagonists inhibited synthesis or receptors of the leukotriene pathways; however, they were incompletely effective and raised the possibility that there were subsets of patients who might respond better than others.<sup>49</sup> New examples include anti-IgE (first Food and Drug Administration [FDA] approval 2003),<sup>52-53</sup> drugs that target interleukin (IL)-4 or IL-13 or both (in phase III clinical trials and in development),<sup>54-58</sup> anti-IL-5

(awaiting FDA approval in 2015),18,59-64 and anti-IL-17 receptor (clinical trial for asthma stopped<sup>65</sup>). Furthermore, it is increasingly clear that the different phenotypes of asthma may be associated with different endotypes, or biologic pathways, for example, T helper (Th)2, Th17, high eosinophils, or high IgE.<sup>66</sup> Because the specific drugs target the critical process that causes asthma in the particular patient, the therapy has to be personalized by matching the pathogenic mechanism and the specific therapy.<sup>67</sup> Thus, it is necessary to develop a biomarker or a set of biomarkers (biomarker profile) that characterizes the underlying disease pathways together with the new therapeutics. Because the process-specific therapies target the critical mediator, it is possible that there may be curative effects that provide long-term relief from the asthma symptoms. However, for anti-IL-5 therapy, this expectation was not met because asthma exacerbations and eosinophils returned when the therapy was withdrawn.<sup>60</sup>

**Biomarkers under development.** These are examples of process-specific biomarkers that are under development (Table 2)<sup>68-71</sup>:

- Total plasma/serum IgE levels or the presence of perennial allergen-specific IgE levels provide a cutoff value for use of anti-IgE therapy.<sup>17</sup>
- Numbers of eosinophils in the blood provide a marker value for the high-eosinophil asthma phenotype for which anti-IL-5 therapy is effective.<sup>18</sup>
- Serum/plasma periostin levels combined with numbers of blood eosinophils and additional biomarkers (eg, plasma eotaxin or IgE) are indicators of patients who respond to therapy with anti-IL-13.<sup>19</sup> In some instances, this profile is referred to as T helper 2 high (Th2-high) asthma. The concept of the Th2-high asthma is challenging because therapies with anti-IgE, anti-IL-5, or anti-IL-13/IL-4 in asthma



BIOMARKER/ASSAY	SAMPLE	INVOLVED PROCESS	DISEASE(S) FOR WHICH BIOMARKER IS:		CITATION
			ESTABLISHED	IN PROMISING DEVELOPMENT	
IgE	Serum, Plasma	Allergy	Asthma	Identification of Th2 endotype in asthma,	17
Eosinophils	Whole Blood	Allergic inflammation		COPD, pulmonary hypertension	18
Periostin	Serum, Plasma	Allergic inflammation		nypertension	19
Chemokines, Th2 response associated	Serum, Plasma	Allergic inflammation			19
Exhaled NO	Exhaled breath	Inflammation	COPD, asthma		20
Pro-BNP	Serum	Heart failure	Pulmonary hypertension		21
iNOS	Sputum, bronchial brushing, BAL	Inflammation		Asthma, COPD, pulmonary hypertension	22, 23
VEGF	Serum, sputum, BAL	Angiogenesis and endo- thelial function		Asthma, COPD, pulmonary hypertension	24–26
ΤΝFα	Serum, sputum, BAL	Inflammation		COPD, asthma	14, 25
Microbiome	Nasal brushing, aseptic BAL	Infection, Colonization, Microbial Flora		Asthma, COPD (pulmonary hypertension)	27–31
Desmosine, isodesmosine	Urine, blood, sputum, BAL	Elastin degradation		COPD, pulmonary hypertension	32–36
Panel of mRNAs/miRNAs	Nasal or bronchial brushing, BAL, sputum, blood	Genomics and epigenetics (changes in gene transcription)		Asthma, COPD (pulmo- nary hypertension)	37–45
Neutrophils	Sputum, BAL	Inflammation		Asthma, COPD	46

#### Table 2. Examples of molecular biomarkers in clinical use or in promising development for asthma, COPD, or pulmonary hypertension.

Notes: Brackets indicate conditions for which certain biomarkers/assays are not commonly used, for example, microbiome testing for pulmonary hypertension. Abbreviations: BAL, bronchoalveolar lavage; IgE, immunoglobulin E; exhaled NO, exhaled nitric oxide; iNOS, inducible nitric oxide synthase; pro-BNP, pro-B-type natriuretic peptide; Th2, T helper 2; TNFα, tumor necrosis factor a; VEGF, vascular endothelial growth factor.

are designed for the T helper 2-high endotype. However, in studies involving Th2-high mouse models (characterized by eosinophils and IgE), airway hyperreactivity and increased airway mucus were inhibited by anti-IL-13<sup>72,73</sup> and not by IgE deficiency<sup>74</sup> or anti-IL-5<sup>74</sup> treatment. Therefore, the biomarker panel for the therapies with anti-IL-13, anti-IL-4, and anti-IL-13 + anti-IL-4 (or anti-IL-4 receptor  $\alpha$ ) is still in development<sup>19,57,58</sup> and is expected to be of great significance for personalized asthma management.

- Sputum-derived molecular signatures of dendritic cells and airway epithelial cells are developed to more specifically understand the type of the immune response and the degree of inflammation.<sup>46</sup> This knowledge is expected to be of great value for assessing the progression of asthma and the response to therapy.
- Biomarkers of critical changes in glucose and lipid metabolism and oxidative stress are also being developed to specifically identify the mechanism that causes non-allergic asthma and asthma that is unresponsive to the therapeutic options detailed above.<sup>27,75–78</sup>

The challenge for biomarker-guided therapy and for biomarker-guided assessment of progression and/or response to therapy is the ability to measure these biomarkers in relatively accessible samples, ie, sputum biomarkers are usually only performed in research centers, whereas blood biomarkers are more easily accessible. An additional level of complexity that is introduced into the clinical algorithm is that the use of these markers makes diagnosis and monitoring of responses to therapy more expensive. The therapeutic dilemma for asthma patients whose biomarker profile does not fit an available specific therapeutic option is challenging. For these cases, bronchodilators and inhaled corticosteroids remain the therapeutic approach of choice, with antimuscarinic agents added when these fail, and few other options. This dilemma is not uncommon as approximately half of the patients who have severe asthma that is not controlled with bronchodilators and inhaled corticosteroids posses a biomarker profile that is not clearly understood,<sup>48,79</sup> and no specific, biomarker-guided therapy is yet available.<sup>80,81</sup>

In conclusion, new asthma biomarkers are under development to better match the disease process with specific therapies. Several challenges remain to be tackled, among them are added costs and the clinical dilemma of patients presented with uncontrolled asthma and a biomarker profile that does not match available new therapies. The combination of specific biomarkers and new therapies is expected to achieve better asthma control with fewer side effects and perhaps long-lasting therapeutic success.

## Asthma COPD Overlap Syndrome

Recent deep phenotyping and biomarker studies have identified asthma/COPD patients who also had a profile suggesting allergic inflammation (Th2-associated inflammation)/ remodeling changes indicative of COPD, a condition known as "Asthma COPD overlap syndrome."82-91 The existence of a syndrome where asthma and COPD overlap was predicted by studies in experimental animals.<sup>92-94</sup> Biomarkers will be necessary to further subtype patients who show signs of this clinical overlap syndrome. For example, specific biomarkers of a Th2 response may identify individuals who might profit from therapy with IL-13/IL-4 inhibitors. Biomarker panels covering both inflammatory and remodeling markers would be particularly informative to determine personalized therapy in these individuals. Specific biomarkers and clinical characteristics need to be further defined by future research.95

# **Development of Biomarkers for COPD**

COPD is the third most common cause of death in the world.<sup>96</sup> COPD is characterized by progressive airflow limitation<sup>97</sup> that is not reversible by bronchodilator drugs. In addition to lung function measurements, imaging (eg, high-resolution CT), bronchoscopy, sputum, and exhaled breath (exhaled NO)<sup>20</sup> are used to assess the nature and the degree of tissue damage to the lungs. A major cause of COPD is exposure to cigarette smoke (primary exposure or indirect exposure via secondhand smoke) although exposure to biomass smoke is a major contributor worldwide.98 Nearly the whole structure of the lungs is affected, including bronchi, small airways, alveoli, blood vessels, and connective tissue. The lung structures can show signs of destruction, leading to a loss of alveoli and subsequent emphysema or scarring and remodeling of the small airways.99 Furthermore, the changes within the tissue from COPD can be a precursor to lung cancer.<sup>100-103</sup>

Measurement of lung function alone presents limitations to determine prognosis, predicting outcomes, selecting appropriate therapy, or monitoring disease activity. Thus, a biomarker that has the potential to identify exacerbations and provides prognostic information on the severity of the disease has long been sought.

**Inflammation.** C-reactive protein (CRP) was the first biomarker to be investigated in COPD,<sup>104–107</sup> and most studies have shown that CRP levels are elevated in COPD patients, both nonsmokers and smokers without airflow obstruction when compared with controls. However, CRP levels are a marker of inflammation and because inflammation is one of the constant processes in COPD, it does not distinguish disease processes or understanding of the specific structure that is being affected in a patient with COPD.

A panel of six inflammatory markers in peripheral blood (white blood cell count, fibrinogen, CRP, IL-6, IL-8, and tumor necrosis factor [TNF]- $\alpha$ ) in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints The chemokine cc-chemokine ligand-CCL18 may also be a component of the serum biomarker signature of inflammation in COPD. CCL18 concentrations were independently associated with the presence of COPD; its concentrations were independently associated with the future risk of cardiovascular hospitalization and mortality and with total mortality in COPD. Lastly, an intervention study showed that short-term steroid use modified serum CCL18 levels.<sup>109</sup>

Sputum neutrophil count has been used as a biomarker to evaluate responses to COPD therapies. The advantage of this biomarker is that it is measured locally in the sputum and reflects inflammation in the airways. There is a clear association of increased sputum neutrophils with smoking and COPD progression.<sup>110</sup> The increased neutrophil numbers persisted for at least 1 year, even following smoking cessation, when measured in the sputum<sup>111</sup> or in biopsy<sup>112</sup> specimens.

Vascular changes. Pulmonary vascular changes are an integral component of COPD.<sup>22</sup> The vascular abnormalities can present as pulmonary hypertension associated with COPD.<sup>113</sup> Accordingly, biomarkers that determine endothelial cell function are associated with COPD. One example is inducible NO synthase that produces NO and contributes to oxidative and nitrosative stress in COPD.<sup>22</sup> Another biomarker example is vascular endothelial growth factor (VEGF). A significant difference in plasma VEGF levels between healthy control and COPD patients and correlation between plasma VEGF and FEV, (forced expiratory volume in 1 second) was shown.<sup>114</sup> Similarly, a decrease in sputum VEGF was correlated with COPD severity.<sup>115</sup> Animal model studies have clearly established that inhibition of VEGF can cause emphysema<sup>116,117</sup> and prepares the vascular bed for remodeling in response to a second stressor (eg, combination of VEGF blockade and hypoxia<sup>24</sup>). As part of a larger panel, biomarkers of endothelial cell function are expected to be a valuable means to determine disease status.

**Systemic organ involvement.** COPD is a systemic disease associated with skeletal muscle wasting.<sup>118,119</sup> Serum levels of chemokines (cx-chemokine ligand-CXCL9, CXCL10) were correlated with energy metabolism genes in skeletal muscles of COPD patients.<sup>120</sup> CT imaging of skeletal muscle mass shows promise as a marker of COPD severity and for the identification of gender-specific differences in COPD.<sup>121,122</sup> Serum myostatin<sup>123,124</sup> and serum creatinine<sup>125</sup> are also under investigation as biomarker of skeletal muscle function in COPD. High levels of serum creatinine are seen following acute muscle destruction while abnormally low levels indicate skeletal muscle atrophy.<sup>125</sup> Serum creatinine in addition to other kidney function markers is also an indicator of renal disease in COPD.<sup>126</sup> Circulating microRNA (miRNA) species are discussed in more detail under emerging biomarkers



and are being considered as markers of muscle wasting in COPD.  $^{\rm 39}$ 

Oxidative and nitrosative stress. A continuum of oxidative stress in virtually all cells in the lungs is thought to be another major pathogenic event in COPD.<sup>22,127-130</sup> Oxidative (and nitrosative) stress is chemically characterized by the exposure to exogenous or endogenous radicals of oxygen or nitrogen. In addition to proinflammatory signals, the radicals are highly reactive and modify proteins and nucleic acids. The modified (eg, nitrosylated) proteins can lose proper function and therefore cause critical cell damage.<sup>22</sup> These processes are thought to be the basis for remodeling changes in the pulmonary blood vessels of COPD patients, which in turn causes COPD-associated pulmonary hypertension.<sup>22</sup> Biomarkers that would precisely reflect the source of the free radical for example, oxidants in cigarette smoke, increased activity of inducible NO synthase, or decreased expression of antioxidant proteins that are in turn controlled by nuclear factor (erythroid-derived 2)-like 2 (NFE2 L2-NRF2) - could lead to the development of specific therapies.<sup>22,131</sup> Therapy with nonspecific antioxidants has been evaluated in COPD. These have failed perhaps due to the inability to precisely and sufficiently target the root process that is causing the oxidative or nitrosative stress.<sup>132</sup>

Assessment of structural cell and stromal function. Biomarkers that assess the function of lung cells in COPD<sup>133</sup> include club (Clara) cell secretory protein (CCSP, CC-16134) and surfactant protein D (SP-D135,136). CCSP is produced almost exclusively by nonciliated, secretory club cells (formerly Clara cells).<sup>137–139</sup> Club cells are transitional precursor cells for ciliated airway epithelial cells,140,141 and type II epithelial cells lining the alveoli produce surfactant proteins.<sup>142</sup> Serum CCSP levels were measured in 2083 patients with COPD (ECLIPSE cohort).143 Serum CCSP levels were reduced in patients with COPD, and there was a correlation with disease severity in former smokers.<sup>143</sup> In the ECLIPSE cohort study, SP-D was higher in current than in former smoker controls but was significantly higher in both current and former smokers diagnosed with COPD.<sup>144</sup> There was a rapid and marked fall in serum SP-D levels among COPD patients who received oral corticosteroids. Its levels returned to baseline following the cessation of treatment,<sup>144</sup> but the risk of exacerbations increased with increasing baseline serum SP-D levels.144-146 However, after acute exposure to cigarette smoke, CCSP serum levels have been shown to be increased<sup>147</sup> or suppressed<sup>148</sup> by inhaled corticosteroids.

Unchecked and increased protease activity causes tissue destruction and emphysema in COPD.<sup>149–153</sup> In addition to the destruction of the alveolar wall, the composition of the lung's matrix is also significantly altered in COPD. Sand et al.<sup>154</sup> found significantly elevated levels of circulating biomarkers of collagen types III, IV, and VI and elastin at the time of COPD exacerbation when compared with that during follow-up. The tissue turnover balance, assessed systemically by the

collagen degradation/formation ratio, increased for type III and VI collagen and decreased for type IV collagen.

Desmosine and isodesmosine are small degradation peptides of elastin and can be measured by mass spectrometry in the plasma and urine. Associations between desmosines and several lung function variables suggest that desmosines, particularly those measured in urine, may be a useful biomarker of ongoing lung destruction in COPD.<sup>32,35,36,155–157</sup>

Alpha-1 antitrypsin is a major endogenous inhibitor of serine proteases such as neutrophil elastase and has therapeutic application in COPD with focus on emphysematous changes<sup>158</sup> because cigarette smoking induces functional deficiency of this inhibitor in the lungs.<sup>159</sup> Individuals who have a loss-of-function mutation in the  $\alpha 1$  antitrypsin have increased risk of developing emphysema.<sup>160,161</sup> Plasma desmosine values did not significantly change following therapy with  $\alpha 1$  antitrypsin in deficient individuals,162 perhaps indicating that the  $\alpha 1$  antitrypsin did not fully inhibit the excess protease activity in this initial study. Later studies showed a significant effect of  $\alpha 1$  antitrypsin replacement therapy in lowering desmosine and isodesmosine levels in plasma and bronchoalveolar lavage fluid.<sup>163</sup> These data again suggested the utility of desmosine and isodesmosine as biomarkers of matrix turnover in the lungs.<sup>36,157,164,165</sup>

In addition to the serine proteases, metalloproteinases (MMPs) also have major destructive activity in COPD.<sup>151,152</sup> Both metalloelastases<sup>166</sup> and metallocollagenases<sup>151</sup> contribute to the process. The proteolytic activity of MMPs is inhibited by tissue inhibitors of metalloproteinases (TIMPs). Concentrations of MMPs and TIMPs in the serum or sputum, as well as the molar ratio between MMPs and TIMPs, are currently being evaluated for their use as a marker of COPD severity, predictors of COPD exacerbations, with specific focus on emphysematous changes.<sup>167–170</sup>

Protease inhibitors with broad-spectrum activity have therapeutic potential in COPD. However, the challenge is that matrix protein turnover is critical for lung health and requires proteases at optimal activity levels. Biomarkers of matrix turnover and therapies that would normalize matrix could greatly aid the management of COPD and also all diseases that cause lung fibrosis.

**Progression of COPD from the inflammatory and remodeling condition to lung cancer.** Large-scale proteomic profiling has revealed a biomarker panel that is hoped to aid in the detection of the emergence of lung cancer in the continuum of changes in the cells from the lungs of COPD patients.<sup>100,101,103</sup> Proteomic and genomic profiling of epithelial cells obtained from buccal or nasal swabs showed that molecular programming of these cells reflected changes in airway epithelial cells,<sup>102</sup> further emphasizing inhaled exposures to toxic substances as a cause of COPD.<sup>38</sup> The search for biomarkers that will identify endotypes of COPD is still under intense investigation and is expected to significantly improve the management of this disease.<sup>86,171–174</sup> It is to be emphasized that in all studies a multimolecular signature was necessary to cluster the patients who had COPD and cancer. The signature comprised, for example, five diagnostic and six normalization proteins in plasma samples,<sup>103</sup> 59 genes in the airway transcriptome,<sup>102</sup> or 13 proteins in the blood.<sup>101</sup> These data suggest that a biomarker test that is useful for cancer diagnosis in COPD patients will be multimolecular and can be performed in blood<sup>101</sup>/plasma<sup>103</sup> samples and in nasal and buccal epithelial samples.<sup>102</sup> This latter property is important because it suggests that the multimolecular biomarker test can be performed on samples that can be acquired noninvasively.

#### **Biomarkers for Pulmonary Hypertension**

Pulmonary hypertension has multiple etiologies. It can be considered a stand-alone condition (eg, idiopathic, heritable, or high-intensity exercise-induced pulmonary hypertension) or as an exacerbating change in obstructive sleep apnea and many lung, heart, blood, and autoimmune diseases.<sup>175</sup> The diagnosis of pulmonary hypertension can predict a short survival rate (eg, 15% mortality rate over 1- to 2-year period for heritable pulmonary hypertension and even higher mortality rate for systemic sclerosis-associated pulmonary hypertension).<sup>175</sup> Pulmonary hypertension can occur alone or in association with many different diseases, and it is classified into five groups by World Health Organization (WHO). The available drugs are targeted for specific WHO groups.<sup>175</sup>

Pulmonary hypertension is characterized by remodeling in the pulmonary vascular bed and can affect the pulmonary artery or vein. Functional measures of right heart function, pulmonary artery pressure, imaging of the right heart (Table 1), and a circulating biomarker of cardiomyocytes<sup>176</sup> (N-terminal pro-B-type natriuretic peptide, pro-BNP; Table 2) are in clinical use for pulmonary hypertension. Furthermore, mutations in several genes, most importantly in the bone morphogenetic protein receptor type 2 (BMPR2) gene,<sup>177–180</sup> increase the risk of developing pulmonary hypertension significantly. The identification of these mutations by a genetic screening test is being used to aid carriers of the mutated genes with additional monitoring.

Current studies are under way to identify additional biomarkers that would help to better match pulmonary hypertension to optimal therapies and to better understand disease pathogenesis.<sup>181</sup> For example, pulmonary hypertension in association with COPD can be the result of diffuse changes in the lung's structure, affecting the airspaces and the vasculature, and in that case, patients would benefit from targeted pulmonary vasodilator therapies.<sup>114</sup> In this situation, the exposure to toxic substances, eg, cigarette smoke, could have a primary impact on the pulmonary vasculature and the associated lung structure and less impact on inflammation.<sup>22</sup> Conversely, pulmonary hypertension in association with COPD can also be the result of focal tissue remodeling of the airways, alveoli, and blood vessels caused by foci of inflammation or foci of oxidative/nitrosative stress.<sup>114</sup> In that case,



vasoconstriction is function-preserving because it restricts blood flow to the remodeled, nonfunctional areas of the lungs and instead directs blood to areas of the lungs that are less remodeled and still have gas-exchange activity. Therefore, administration of vasodilators would not be helpful and could worsen the condition.<sup>113</sup>

Desmosine and isodesmosine, two amino acids that form cross-linkages in elastin, are also being evaluated as biomarkers of matrix turnover in pulmonary vascular remodeling.<sup>182</sup> This is hoped to detect the abnormal elastin and collagen content and turnover that is a critical process in the remodeling of the vascular bed in pulmonary hypertension.<sup>183–188</sup>

Pulmonary hypertension can be associated with autoimmune diseases that manifest in generalized connective tissue remodeling (eg, systemic sclerosis). In some of these cases, specific immune dysfunction can induce pulmonary hypertension, and specific biomarkers are being sought that would match patients with specific immune inhibitors (eg, anti-IL-1,<sup>189</sup> anti-IL-6,<sup>189</sup> anti-IL-13/IL-4,<sup>190,191</sup> anti-IL-17,<sup>192</sup> or interferon<sup>190</sup>). Animal model studies suggest that the immune mediators have a causal relationship with vascular remodeling and increased right ventricular pressures.<sup>193–198</sup> Therefore, the expectation is that specific biomarkers of the immune processes will be important guides for personalized therapy in pulmonary hypertension associated with significant inflammation.

Several large multicenter clinical trials (eg, Pulmonary Vascular Disease OMICS (PVDOMICS)) are currently under way to identify additional biomarker candidates in a variety of types of pulmonary hypertension, including those with underlying parenchymal lung disease.

#### **Biomarkers of Environmental Exposures**

Environmental exposures exacerbate all chronic lung diseases by inducing oxidative stress or inflammation, directly injuring the cells that line the airspaces, and causing associated damage to the cardiovascular system and increased mortality.<sup>199–201</sup> Techniques to measure fine dusts and volatile chemicals such as ozone in air are well established.<sup>202,203</sup> Tracers are available that track the source of the fine dusts and distinguish between fossil fuel<sup>204</sup> and biomass (plant) combustion<sup>205–208</sup> or identify fungal products in indoor air.<sup>209</sup>

Additionally, there are several examples of drugs that can cause chronic lung disease or exacerbate an existing condition<sup>210</sup>: aspirin<sup>211</sup> or angiotensin-converting enzyme inhibitors<sup>212</sup> can cause asthma; fenfluramine/phentermine (a weight loss drug) can cause pulmonary hypertension<sup>213</sup>; fenretinide (a cancer drug) can cause emphysema<sup>214</sup>; bleomycin (a cancer drug)<sup>215</sup> can cause parenchymal inflammation and interstitial fibrosis; and kinase inhibitor cancer drugs<sup>175</sup> can cause pulmonary hypertension. Naturally occurring toxins have also been linked to chronic lung disease, for example, molds in waterdamaged houses<sup>209</sup> and asthma/COPD or monocrotaline (from many types of plants)<sup>216</sup> and pulmonary hypertension. In all these cases, the relationship between the natural or drug toxicity and the chronic lung disease could be causally resolved by combining studies in human subjects and animal models.

Biomarkers that would quantify environmental exposures of the lungs and establish an etiology of exposure for the chronic lung disease are much less established. Causality of exposure is established for silica/coal dust exposure causing bronchitis and pulmonary hypertension, 217,218 as is cigarette smoke exposure and COPD.98 Cotinine is a specific and sensitive serum marker for cigarette smoke exposure and in large epidemiologic studies shows the detrimental effects of exposure to secondhand cigarette smoke.<sup>219,220</sup> However, more specific chemicals need to be measured to determine the individual exposure to specific toxins in tobacco smoke.<sup>221</sup> Levels of IgE antibodies or asthma exacerbations to indoor or outdoor allergens are an indirect measure of exposure because responses occur in at-risk or in sensitized individuals.<sup>222,223</sup> For example, high IgE levels may be produced by exposure to large doses of allergen or low doses of allergen in a highly sensitized individual. Direct detection of particles in induced sputum<sup>224–228</sup> or bronchoalveolar lavage<sup>229</sup> is possible when the exposure levels are very high (as occurred during the World Trade Center disaster) or is the result of occupational exposures. However, these measures lack specific quantification. Current research efforts are directed toward the identification of biomarkers that predict increased risk of developing chronic lung diseases and other detrimental health effects due to occupational, residential, or outdoor ambient exposures.<sup>230–235</sup> The tests under development are not yet specific for the exposure but indicate protective or injurious metabolic, inflammatory, or tissue remodeling activities. Environmental disasters such as the World Trade Center collapse are being used to identify biomarkers that would detect individuals at risk for the development of chronic progressive lung disease in response to the exposures.<sup>236–239</sup>

## **Emerging Classes of Biomarkers**

Gene and protein expression has been the paradigm for biomarker studies, and these classes of biomarkers, particularly messenger RNA (mRNA) measured by polymerase chain reaction or proteins determined by enzyme-linked immunosorbent assay (ELISA or multiplex ELISA) or proteins determined by mass spectrometry assays, have been used for the biomarkers that are currently in clinical development. New classes of biological molecules are emerging as potential sources of valuable biomarker information as outlined below.

**Noncoding RNA.** Noncoding RNA species are being evaluated for their utility in many different disease processes, including all types of chronic lung diseases. One class of noncoding RNA, miRNA, serves not only for communication between adjacent cells but also between cells from different organs. miRNA is packaged in exosomes or adheres to carrier proteins and then exported into the blood and to other extracellular spaces. Therefore, levels of specific miRNAs can be determined in serum, plasma, and exosomal fractions of plasma, serum, sputum, or bronchoalveolar lavage.<sup>41,42</sup> Specific miRNAs are being investigated for their role in disease pathogenesis and also as potential biomarker in all chronic lung diseases, including asthma,<sup>43,45,240–244</sup> COPD,<sup>37,40,245,246</sup> muscle wasting in COPD,<sup>39,123,247</sup> and pulmonary hypertension.<sup>248–256</sup> Although there is great enthusiasm, currently none of the miRNA species has been established as a clinical biomarker for chronic lung diseases.

**Metabolites.** Biomarkers that detect molecular changes in metabolism are also emerging as important contributors to virtually all chronic lung diseases. For example, major adipokines leptin and adiponectin were reported to be abnormally regulated in COPD and related to systemic inflammation, body mass index (BMI), and gender.<sup>257</sup> Resistin, another adipokine, is under investigation as a biomarker in asthma.<sup>258</sup> Furthermore, many cases of severe treatment-refractory asthma and cases of pulmonary hypertension are thought to be associated with severe reprogramming of metabolism and high BMI.<sup>259–261</sup> Mutations in the bone morphogenetic protein receptor 2 gene that increase the risk of developing pulmonary hypertension are now thought to cause reprogramming of cardiac lipid storage and glucose metabolism.<sup>262,263</sup>

Biomarkers of metabolic remodeling in the pulmonary vasculature and right heart are expected to be of diagnostic and prognostic value in pulmonary hypertension.<sup>264–268</sup> Lower circulating levels of the soluble receptor for advanced glycation end products (RAGE) were associated with the severity of COPD, specifically emphysema, and a genetic polymorphisms in the RAGE gene locus.<sup>269</sup> Lower RAGE levels were also associated with neutrophilic asthma.<sup>270</sup> However, animal models suggest that the role of RAGE in asthma requires further studies because in the model the presence of RAGE is critically required for the asthmatic response to natural allergens.<sup>271</sup>

**Vitamins.** Vitamins have been widely studied for their contribution to chronic lung diseases, and vitamin levels can be used to determine increased risk for developing disease. In the ECLIPSE study, low levels of vitamin D in blood – reflecting insufficient nutritional intake and insufficient exposure to sunlight – were related to the presence of emphysema, exercise capacity, airways reactivity, and blood CCSP levels.<sup>272</sup> Abnormally low circulating levels of vitamin D have been related to exacerbations of asthma and asthma susceptibility.<sup>273</sup> However, vitamin D as an add-on therapy for asthma has shown inconsistent results,<sup>274,275</sup> suggesting that an optimal level of vitamin D may be required.

**Coagulation markers.** Coagulation markers have long been implicated in chronic lung diseases. Serum von Willebrand factor, a glycoprotein that is a marker of endothelial cells and initiates coagulation, has been reported to indicate early structural and functional changes of the pulmonary vasculature and to be an interesting marker for COPD.<sup>276</sup> Inflammation in the lungs causes another coagulation cascade initiation protease, tissue factor activity to be expressed and

to be released via exosomes from mononuclear cells, airway epithelial cells, and endothelial cells.<sup>277,278</sup> By this mechanism, tissue factor causes increased coagulation due to inflammation or tissue injury, including asthma.<sup>279–281</sup> Abnormally increased or decreased coagulation leading to pulmonary intravascular thrombosis or contributing to pulmonary hemorrhage can be seen in pulmonary hypertension.<sup>282–285</sup>

Microbiome. Markers to distinguish an intact microbiome from a microbiome that protects, predisposes, or causes disease are being refined in ongoing research.<sup>31,286-288</sup> The most frequently used methodology consists of deep sequencing of 16S ribosomal (r)RNA of bacteria.<sup>289,290</sup> Additionally, sequencing methods to study the fungal and viral microbiomes and metabolic state of a specific microbiome are in development as tool for the understanding of chronic lung diseases.<sup>28,291</sup> The sequencing approach circumvents the necessity to culture bacteria, virus, or fungi and allows for detection of microbes that cannot be cultured. Furthermore, sequencing allows the vastness of the microbiome to be appreciated. Changes in the microbiome of the lungs in COPD are currently being mapped out to understand the recurrent microbial infections that cause hospitalizations and exacerbations of COPD.<sup>29,30,291,292</sup> Viral infections, including rhinovirus<sup>293</sup> and respiratory syncytial virus,<sup>294</sup> are thought to initiate asthma in early life and are major triggers of exacerbations in asthma patients of all ages.<sup>295,296</sup> Furthermore, when compared with controls, patients with uncontrolled asthma had a higher microbiota burden in the airways.<sup>297</sup>

#### Conclusions

The lungs are catching up with many other organs for the availability of molecular biomarkers that would indicate molecular disease processes or detect injury to specific cell types in the lungs. The readily available specific lung and right heart function tests may have slowed the discovery of molecular biomarkers. In addition to lung and right heart function tests, imaging was also developed early, with bronchoscopy providing for direct inspection of airways and the ability to obtain biopsies of lung and lung-draining lymph node tissue under visual guidance.<sup>298</sup> Furthermore, high-resolution CT, positron emission tomography, and magnetic resonance imaging scans are allowing for detailed imaging of lungs and heart.<sup>299-303</sup> The disadvantages of the above tests include the specialized equipment, the invasiveness of some of the procedures (bronchoscopy, right heart catheterization), and the time required and the potential for radiation exposure by the imaging procedure.304-306

New therapies that are specific to a molecular pathway are still in clinical trials or have been approved during the past 10 years, eg, anti-IgE or anti-IL-13/anti-IL-4 for asthma. These new therapies have provided demand to identify molecular biomarkers so that therapies can be personalized for the disease driving molecular process.<sup>19,57,62,307,308</sup> Improved therapies and management of a deadly condition, pulmonary hypertension, have led to improved quality of life and increased life expectancy.<sup>309</sup> This clinical success in pulmonary hypertension has created demand for the development of molecular biomarkers for early detection and better matching of aberrant disease-causing molecular process and therapy.<sup>21,113,310</sup> Improved detailed imaging of lungs of COPD patients has resulted in the detection of early changes in the lung structure,<sup>311</sup> and there is a great demand for prognostic biomarkers.<sup>101,103,173,174</sup>

For these reasons, it is expected that in the future molecular biomarkers will become critically important tools for the clinical management of many of the chronic lung diseases.

#### **Author Contributions**

Idea for the review: GG. Writing of the manuscript: GG, ND. Preparation of the tables: GG, AB. Finding of references: GG, ND, AB, JR. Editing: GG, AB, S-HP, SP, BB, JR, EB-R, ND. All authors reviewed and approved of the final manuscript.

#### REFERENCES

- Decramer M, Cooper CB. Treatment of COPD: the sooner the better? *Thorax*. 2010;65(9):837–41.
- Rabe KF, Wedzicha JA. Controversies in treatment of chronic obstructive pulmonary disease. *Lancet*. 2011;378(9795):1038–47.
- 3. Martinez FD, Vercelli D. Asthma. Lancet. 2013;382(9901):1360-72.
- Gibbs JSR, Coghlan JG, Kiely DG, Wort SJ. Pulmonary hypertension in UK clinical practice: an update. *Br J Cardiol.* 2015;22(1):S2–15.
- Austin ED, Kawut SM, Gladwin MT, Abman SH. Pulmonary hypertension: NHLBI workshop on the primary prevention of chronic lung diseases. *Ann Am Thorac Soc.* 2014;11(suppl 3):S178–85.
- (GINA) GINA. The Global Strategy for Asthma Management and Prevention. 2015. Available at: http://www.ginasthma.org/.
- Barnes P, Kharitonov S. Exhaled nitric oxide: a new lung function test. *Thorax*. 1996;51(3):233.
- Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J.* 2005;26(5):948–68.
- Cander L, Comroe JH. A method for the objective evaluation of bronchodilator drugs. J Allergy. 1955;26(3):210–8.
- Sont JK, Willems LN, Bel EH, van Krieken JHJ, Van den Broucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. *Am J Respir Crit Care Med.* 1999;159(4):1043–51.
- Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. JAm Coll Cardiol. 2009;54(1s1):S55–66.
- Cazzola M, MacNee W, Martinez FJ, et al. American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. *Eur Respir J.* 2008;31(2):416–69.
- Haccuria A, Michils A, Michiels S, Van Muylem A. Exhaled nitric oxide: a biomarker integrating both lung function and airway inflammation changes. *J Allergy Clin Immunol.* 2014;134(3):554–9.
- Sakao S, Tatsumi K, Igari H, et al. Association of tumor necrosis factor-α gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD. *Chest.* 2002;122(2):416–20.
- Mah K, Caldwell CB, Ung YC, et al. The impact of 18 FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. *Int J Rad Oncol Biol Phys.* 2002;52(2):339–50.
- Snell N, Newbold P. The clinical utility of biomarkers in asthma and COPD. Curr Opin Pharmacol. 2008;8(3):222-35.
- Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. *J Allergy Clin Immunol.* 2001;108(2):184–90.
- Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. *Ann Am Thorac Soc.* 2014;11(4):531–6.
- Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–98.
- Dweik RA, Boggs PB, Erzurum SC, et al. American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med*. 2011;184(5):602–15.



- Foris V, Kovacs G, Tscherner M, Olschewski A, Olschewski H. Biomarkers in pulmonary hypertension: what do we know? *Chest.* 2013;144(1):274–83.
- Seimetz M, Parajuli N, Pichl A, et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. *Cell*. 2011;147(2):293–305.
- Yamamoto M, Tochino Y, Chibana K, Trudeau JB, Holguin F, Wenzel SE. Nitric oxide and related enzymes in asthma: relation to severity, enzyme function and inflammation. *Clin Exp Allergy*. 2012;42(5):760–8.
- Voelkel NF, Cool C, Taraceviene-Stewart L, et al. Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. *Crit Care Med.* 2002;30(5 suppl):S251–6.
- Manthei DM, Schwantes EA, Mathur SK, et al. Nasal lavage VEGF and TNFalpha levels during a natural cold predict asthma exacerbations. *Clin Exp Allergy*. 2014;44(12):1484–93.
- Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. *Nat Med.* 2004;10(10):1095–103.
- 27. Bunyavanich S, Schadt EE. Systems biology of asthma and allergic diseases: a multiscale approach. *J Allergy Clin Immunol.* 2015;135(1):31–42.
- Cui L, Lucht L, Tipton L, et al. Topographic diversity of the respiratory tract mycobiome and alteration in HIV and lung disease. *Am J Respir Crit Care Med.* 2015;191(8):932–42.
- Dickson RP, Huang YJ, Martinez FJ, Huffnagle GB. The lung microbiome and viral-induced exacerbations of chronic obstructive pulmonary disease: new observations, novel approaches. *Am J Respir Crit Care Med.* 2013;188(10):1185–6.
- 30. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. *PLoS One*. 2011;6(2):e16384.
- Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease. *Thorax.* 2012;67(5):456–63.
- Liu X, Ma S, Liu S, Liu M, Turino G, Cantor J. The ratio of free to bound desmosine and isodesmosine may reflect emphysematous changes in COPD. *Lung.* 2015;193(3):329–34.
- Huang JT, Chaudhuri R, Albarbarawi O, et al. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. *Thorax.* 2012;67(6):502–8.
- Lindberg CA, Engstrom G, de Verdier MG, et al. Total desmosines in plasma and urine correlate with lung function. *Eur Respir J.* 2011;39(4):839–45.
- Ma S, Lin YY, Turino GM. Measurements of desmosine and isodesmosine by mass spectrometry in COPD. *Chest.* 2007;131(5):1363–71.
- Ma S, Lieberman S, Turino GM, Lin YY. The detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum. *Proc Natl Acad Sci U S A*. 2003;100(22):12941–3.
- Ezzie ME, Crawford M, Cho JH, et al. Gene expression networks in COPD: microRNA and mRNA regulation. *Thorax*. 2012;67(2):122–31.
- Gower AC, Steiling K, Brothers JF II, Lenburg ME, Spira A. Transcriptomic studies of the airway field of injury associated with smoking-related lung disease. *Proc Am Thorac Soc.* 2011;8(2):173–9.
- Donaldson A, Natanek SA, Lewis A, et al. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. *Thorax*. 2013;68(12):1140–9.
- Molina-Pinelo S, Pastor MD, Suarez R, et al. MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD. *Eur Respir J.* 2014;43(6):1740–9.
- Simpson LJ, Patel S, Bhakta NR, et al. A microRNA upregulated in asthma airway T cells promotes TH2 cytokine production. *Nat Immunol.* 2014;15(12): 1162–70.
- Solberg OD, Ostrin EJ, Love MI, et al. Airway epithelial miRNA expression is altered in asthma. *Am J Respir Crit Care Med*. 2012;186(10):965–74.
- Takyar S, Vasavada H, Zhang JG, et al. VEGF controls lung Th2 inflammation via the miR-1-Mpl (myeloproliferative leukemia virus oncogene)-P-selectin axis. *J Exp Med.* 2013;210(10):1993–2010.
- Wang M, Huang Y, Liang Z, et al. Plasma miRNAs might be promising biomarkers of chronic obstructive pulmonary disease. *Clin Respir J.* 2014 Aug 8. doi: 10.1111/crj.12194.
- Bleck B, Grunig G, Chiu A, et al. MicroRNA-375 regulation of thymic stromal lymphopoietin by diesel exhaust particles and ambient particulate matter in human bronchial epithelial cells. *J Immunol.* 2013;190(7):3757–63.
- Bleck B, Kazeros A, Bakal K, et al. Coexpression of type 2 immune targets in sputum-derived epithelial and dendritic cells from asthmatic patients. J Allergy Clin Immunol. 2015;136(3):619.e5–27.e5.
- Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. *N Engl J Med.* 1989;320(5):271–7.
- Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. *Am J Respir Crit Care Med.* 1999;160(3): 1001–8.
- Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. *New Engl J Med.* 1999;340(3):197–206.

- Bell MC, Busse WW. Severe asthma: an expanding and mounting clinical challenge. J Allergy Clin Immunol. 2013;1(2):110–21. quiz 122.
- Busse W, Spector S, Rosen K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. *J Allergy Clin Immunol.* 2013;132(2):485.e11-6.e11.
- Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. *New Engl J Med.* 2011;364(11): 1005–15.
- Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. *J Allergy Clin Immunol.* 2014;2(5):525.e1–36.e1.
- Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. *Am J Respir Crit Care Med.* 2010;181(8):788–96.
- De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014;133(4):989–96.
- Fajt ML, Wenzel SE. Biologic therapy in asthma: entering the new age of personalized medicine. J Asthma. 2014;51(7):669–76.
- Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015;135(2):299–310. quiz 311.
- 58. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. *N Engl J Med*. 2013;368(26):2455-66.
- Bel EH, Wenzel SE, Thompson PJ, et al. SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-97.
- Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. *J Allergy Clin Immunol.* 2014;133(3):921–3.
- Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. *Eur Respir J.* 2014;44(1): 239–41.
- Ortega H, Li H, Suruki R, Albers F, Gordon D, Yancey S. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. *Ann Am Thorac Soc.* 2014;11(7):1011–7.
- Ortega HG, Liu MC, Pavord ID, et al. MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207.
- Wechsler ME, Fulkerson PC, Bochner BS, et al. Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol. 2012;130(3):563-71.
- Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebocontrolled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. *Am J Respir Crit Care Med.* 2013;188(11): 1294–302.
- Lötvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–60.
- Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol. 2012;130(4):829–42.
- Arron JR, Choy DF, Scheerens H, Matthews JG. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. *Ann Am Thorac Soc.* 2013;10(suppl):S206–13.
- Bhakta NR, Solberg OD, Nguyen CP, et al. A qPCR-based metric of Th2 airway inflammation in asthma. *Clin Transl Allergy*. 2013;3(1):24.
- Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. *Am J Respir Crit Care Med.* 2013;187(8):804–11.
- Jia G, Erickson RW, Choy DF, et al. Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. *J Allergy Clin Immunol.* 2012;130(3):647.e10–654.e10.
- Grünig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. *Science*. 1998;282(5397):2261–3.
- Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. *Science*. 1998;282(5397):2258–61.
- Corry DB, Grünig G, Hadeiba H, et al. Requirements for allergen-induced airway hyperreactivity in T and B cell-deficient mice. *Mol Med.* 1998;4(5):344–55.
- Adamko DJ, Sykes BD, Rowe BH. The metabolomics of asthma: novel diagnostic potential. *Chest.* 2012;141(5):1295–302.
- Jung J, Kim SH, Lee HS, et al. Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. *Clin Exp Allergy*. 2013;43(4): 425–33.
- Marozkina NV, Wang XQ, Stsiapura V, et al. Phenotype of asthmatics with increased airway S-nitrosoglutathione reductase activity. *Eur Respir J.* 2015;45(1):87–97.
- Holguin F, Bleecker ER, Busse WW, et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol. 2011;127(6):1486.e2– 93.e2.



- Brasier AR, Victor S, Ju H, et al. Predicting intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines. *Clin Transl Sci.* 2010;3(4):147–57.
- Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. *Am J Respir Crit Care Med.* 2009;180(5):388-95.
- Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol. 2015;15(1):57-65.
- Yamauchi Y, Yasunaga H, Matsui H, et al. Comparison of in-hospital mortality in patients with COPD, asthma and asthma-COPD overlap exacerbations. *Respiralogy*. 2015;20(6):940-6.
- Kiljander T, Helin T, Venho K, Jaakkola A, Lehtimaki L. Prevalence of asthma-COPD overlap syndrome among primary care asthmatics with a smoking history: a cross-sectional study. *NPJ Prim Care Respir Med.* 2015;25:15047.
- Golpe R, Perez de Llano L. Are the diagnostic criteria for asthma-COPD overlap syndrome appropriate in biomass smoke-induced chronic obstructive pulmonary disease? *Arch Bronconeumol.* 2015 Mar 19. pii: S0300-2896 (15) 00065-4. doi: 10.1016/j.arbres.2014.12.016. [Epub ahead of print].
- Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. *Thorax*. 2015;70(7):683–91.
- Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2015;191(7):758–66.
- Bellanti JA, Settipane RA. For the patient. The asthma-COPD overlap syndrome (ACOS): is it asthma? Is it COPD? Or is it both? *Allergy Asthma Proc.* 2015;36(1):87.
- Fu JJ, McDonald VM, Gibson PG, Simpson JL. Systemic inflammation in older adults with asthma-COPD overlap syndrome. *Allergy Asthma Immunol Res.* 2014;6(4):316–24.
- Fu JJ, Gibson PG, Simpson JL, McDonald VM. Longitudinal changes in clinical outcomes in older patients with asthma, COPD and asthma-COPD overlap syndrome. *Respiration*. 2014;87(1):63–74.
- McDonald VM, Higgins I, Gibson PG. Insight into older peoples' healthcare experiences with managing COPD, asthma, and asthma-COPD overlap. *J Asthma*. 2013;50(5):497–504.
- Zeki AA, Schivo M, Chan A, Albertson TE, Louie S. The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy (Cairo). 2011;2011:861926.
- Elias J. The relationship between asthma and COPD. Lessons from transgenic mice. *Chest.* 2004;126(2 suppl):111S–6S. discussion 159S–61S.
- Elias JA, Kang MJ, Crothers K, Homer R, Lee CG. State of the art. Mechanistic heterogeneity in chronic obstructive pulmonary disease: insights from transgenic mice. *Proc Am Thorac Soc.* 2006;3(6):494–8.
- Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000;106(9):1081–93.
- Reddel HK. Treatment of overlapping asthma-chronic obstructive pulmonary disease: can guidelines contribute in an evidence-free zone? J Allergy Clin Immunol. 2015;136(3):546–52.
- Burney PG, Patel J, Newson R, Minelli C, Naghavi M. Global and regional trends in COPD mortality, 1990–2010. *Eur Respir J.* 2015;45(5):1239–47.
- Celli BR, MacNee W, Agusti A; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J.* 2004;23(6):932–46.
- Eisner MD, Anthonisen N, Coultas D, et al. Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2010;182(5):693–718.
- Barnes PJ. Hepatocyte growth factor deficiency in COPD: a mechanism of emphysema and small airway fibrosis? *Chest*. 2014;146(5):1135–6.
- Boelens MC, Gustafson AM, Postma DS, et al. A chronic obstructive pulmonary disease related signature in squamous cell lung cancer. *Lung Cancer*. 2011;72(2):177–83.
- Li XJ, Hayward C, Fong PY, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. *Sci Transl Med.* 2013;5(207): 207ra142.
- Sridhar S, Schembri F, Zeskind J, et al. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. *BMC Genomics*. 2008;9:259.
- Vachani A, Pass HI, Rom WN, et al. Validation of a multiprotein plasma classifier to identify benign lung nodules. J Thorac Oncol. 2015;10(4):629–37.
- 104. de Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. *Chest.* 2008;133(6):1336–43.
- Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2007;175(3):250–5.
- Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2006;174(8):867–74.

- 107. Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. *Am J Respir Crit Care Med.* 2012;185(11): 1218–24.
- 108. Agustí A, Edwards LD, Rennard SI, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. *PLoS One.* 2012;7(5):e37483.
- 109. Sin DD, Miller BE, Duvoix A, et al. ECLIPSE Investigators. Serum PARC/ CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2011;183(9):1187–92.
- 110. Perng DW, Huang HY, Chen HM, Lee YC, Perng RP. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. *Chest.* 2004;126(2):375–81.
- 111. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. *Eur Respir J.* 2005;26(5):835–45.
- Gamble E, Grootendorst DC, Hattotuwa K, et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. *Eur Respir J.* 2007;30(3):467–71.
- Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 suppl):D109–16.
- 114. Aaron SD, Vandemheen KL, Ramsay T, et al. Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. *Respir Res.* 2010;11(1):41.
- Kanazawa H, Yoshikawa J. Elevated oxidative stress and reciprocal reduction of vascular endothelial growth factor levels with severity of COPD. *Chest.* 2005;128(5):3191–7.
- 116. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. *Am J Respir Crit Care Med.* 2001;163(3 pt 1):737–44.
- Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000; 106(11):1311–9.
- Serres I, Gautier V, Varray A, Prefaut C. Impaired skeletal muscle endurance related to physical inactivity and altered lung function in COPD patients. *Chest.* 1998;113(4):900–5.
- 119. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure. *Eur Respir J.* 1990;3(2):192–6.
- Davidsen PK, Herbert JM, Antczak P, et al. A systems biology approach reveals a link between systemic cytokines and skeletal muscle energy metabolism in a rodent smoking model and human COPD. *Genome Med.* 2014;6(8):59.
- 121. Diaz AA, Zhou L, Young TP, et al. ECLIPSE Investigators. Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers. *Acad Radiol.* 2014;21(10): 1255–61.
- 122. McDonald ML, Diaz AA, Ross JC, et al. Quantitative computed tomography measures of pectoralis muscle area and disease severity in chronic obstructive pulmonary disease. A cross-sectional study. *Ann Am Thorac Soc.* 2014;11(3): 326–34.
- 123. Puig-Vilanova E, Martinez-Llorens J, Ausin P, Roca J, Gea J, Barreiro E. Quadriceps muscle weakness and atrophy are associated with a differential epigenetic profile in advanced COPD. *Clin Sci (Lond)*. 2015;128(12):905–21.
- 124. Ju CR, Chen RC. Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease. *Respir Med.* 2012;106(1):102–8.
- 125. Moçin ÖY, Karakurt Z, Şen E, et al. Serum creatinine and weaning in patients with chronic obstructive pulmonary disease: multicenter pilot study. *J Palliative Care Med.* 2013;3:143.
- 126. Yoshizawa T, Okada K, Furuichi S, et al. Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels. *Int J Chron Obstruct Pulmon Dis.* 2015;10:1283–9.
- Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. *World Allergy Organ J.* 2012;5(1):9–19.
- Biswas S, Hwang JW, Kirkham PA, Rahman I. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease. *Curr Med Chem.* 2013;20(12):1496–530.
- 129. Kirkham P, Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. *Pharmacol Ther.* 2006;111(2):476–94.
- Marwick JA, Edirisinghe I, Arunachalam G, et al. Cigarette smoke regulates VEGFR2-mediated survival signaling in rat lungs. *J Inflamm (Lond)*. 2010;7(1):11.
- Malhotra D, Thimmulappa RK, Mercado N, et al. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J Clin Invest. 2011;121(11):4289–302.
- 132. Garber K. Biochemistry: a radical treatment. Nature. 2012;489(7417):S4-6.



- Celli BR, Locantore N, Yates J, et al. ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2012;185(10):1065–72.
- Broeckaert F, Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. *Clin Exp Allergy*. 2000;30(4):469–75.
- 135. Winkler C, Atochina-Vasserman EN, Holz O, et al. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. *Respir Res.* 2011;12:29.
- 136. More JM, Voelker DR, Silveira LJ, Edwards MG, Chan ED, Bowler RP. Smoking reduces surfactant protein D and phospholipids in patients with and without chronic obstructive pulmonary disease. *BMC Pulm Med.* 2010;10:53.
- Hiemstra PS, Bourdin A. Club cells, CC10 and self-control at the epithelial surface. *Eur Respir J.* 2014;44(4):831–2.
- 138. Barnes PJ. Club cells, their secretory protein, and COPD. Chest. 2015; 147(6):1447-8.
- Gamez AS, Gras D, Petit A, et al. Supplementing defect in club cell secretory protein attenuates airway inflammation in COPD. Chest. 2015;147(6):1467–76.
- Pardo-Saganta A, Law BM, Tata PR, et al. Injury induces direct lineage segregation of functionally distinct airway basal stem/progenitor cell subpopulations. *Cell Stem Cell*. 2015;16(2):184–97.
- 141. Pardo-Saganta A, Tata PR, Law BM, et al. Parent stem cells can serve as niches for their daughter cells. *Nature*. 2015;523(7562):597–601.
- Castranova V, Rabovsky J, Tucker JH, Miles PR. The alveolar type II epithelial cell: a multifunctional pneumocyte. *Toxicol Appl Pharmacol.* 1988;93(3): 472–83.
- 143. Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. *Thorax.* 2008;63(12):1058–63.
- 144. Sin DD, Leung R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. *BMC Pulm Med.* 2007;7:13.
- 145. Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA. Regulation of surfactant secretion in alveolar type II cells. *Am J Physiol Lung Cell Mol Physiol*. 2007;293(2):L259–71.
- 146. Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. *Eur Respir J.* 2009;34(1):95–102.
- 147. Lakind JS, Holgate ST, Ownby DR, et al. A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects. *Biomarkers*. 2007;12(5):445–67.
- Alexis NE, Lay JC, Haczku A, et al. Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers. *Environ Health Perspect.* 2008;116(6):799–805.
- Osman M, Cantor JO, Roffman S, Keller S, Turino GM, Mandl I. Cigarette smoke impairs elastin resynthesis in lungs of hamsters with elastase-induced emphysema. *Am Rev Respir Dis.* 1985;132(3):640–3.
- Chrzanowski P, Keller S, Cerreta J, Mandl I, Turino GM. Elastin content of normal and emphysematous lung parenchyma. *Am J Med.* 1980;69(3):351–9.
- Dalal S, Imai K, Mercer B, Okada Y, Chada K, D'Armiento JM. A role for collagenase (Matrix metalloproteinase-1) in pulmonary emphysema. *Chest*. 2000;117(5 suppl 1):227S-8S.
- D'Armiento J, Dalal SS, Okada Y, Berg RA, Chada K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. *Cell*. 1992;71(6):955-61.
- Gross P, Pfitzer EA, Tolker E, Babyak MA, Kaschak M. Experimental emphysema: its production with papain in normal and silicotic rats. *Arch Environ Health.* 1965;11:50–8.
- 154. Sand JM, Knox AJ, Lange P, et al. Accelerated extracellular matrix turnover during exacerbations of COPD. *Respir Res.* 2015;16(1):69.
- Ma S, Turino GM, Hayashi T, Yanuma H, Usuki T, Lin YY. Stable deuterium internal standard for the isotope-dilution LC-MS/MS analysis of elastin degradation. *Anal Biochem.* 2013;440(2):158–65.
- 156. Turino GM, Lin YY, He J, Cantor JO, Ma S. Elastin degradation: an effective biomarker in COPD. 2012;9(4):435–8.
- 157. Luisetti M, Ma S, Iadarola P, et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. *Eur Respir J.* 2008;32(5):1146–57.
- Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest. 1981;68(5):1158–65.
- Gadek JE, Fells GA, Crystal RG. Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans. *Science*. 1979;206(4424): 1315–6.
- Laurell CB, Eriksson S. The electrophoretic α; 1-globulin pattern of serum in α; 1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963;15(2):132–40.
- Eriksson S. Pulmonary emphysema and alpha1-antitrypsin deficiency. *Acta Med Scand.* 1964;175:197–205.

- Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. *Chest.* 2002;122(1):66–74.
- 163. Ma S, Lin YY, He J, Rouhani FN, Brantly M, Turino GM. Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation. COPD. 2013;10(4):473-81.
- Turino GM, Ma S, Lin YY, Cantor JO, Luisetti M. Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2011;184(6):637–41.
- Slowik N, Ma S, He J, et al. The effect of second hand smoke exposure on markers of elastin degradation. *Chest.* 2011;140(4):946–53.
- Morris DG, Huang X, Kaminski N, et al. Loss of integrin alpha(v)beta6mediated TGF-beta activation causes Mmp12-dependent emphysema. *Nature*. 2003;422(6928):169–73.
- 167. Papakonstantinou E, Karakiulakis G, Batzios S, et al. Acute exacerbations of COPD are associated with significant activation of matrix metalloproteinase 9 irrespectively of airway obstruction, emphysema and infection. *Respir Res.* 2015;16(1):78.
- 168. Linder R, Ronmark E, Pourazar J, Behndig A, Blomberg A, Lindberg A. Serum metalloproteinase-9 is related to COPD severity and symptoms – cross-sectional data from a population based cohort-study. *Respir Res.* 2015;16:28.
- Montaño M, Sansores RH, Becerril C, et al. FEV<sub>1</sub> inversely correlates with metalloproteinases 1, 7, 9 and CRP in COPD by biomass smoke exposure. *Respir Res.* 2014;15:74.
- D'Armiento JM, Goldklang MP, Hardigan AA, et al. Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema. *PLoS One*. 2013;8(2):e56352.
- Bhattacharya S, Srisuma S, Demeo DL, et al. Molecular biomarkers for quantitative and discrete COPD phenotypes. *Am J Respir Cell Mol Biol.* 2009; 40(3):359-67.
- 172. Bhattacharya S, Tyagi S, Srisuma S, et al. Peripheral blood gene expression profiles in COPD subjects. *J Clin Bioinforma*. 2011;1(1):12.
- Carolan BJ, Hughes G, Morrow J, et al. The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. *Respir Res.* 2014; 15:127.
- Morrow JD, Qiu W, Chhabra D, et al. Identifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methods. *BMC Med Genomics.* 2015;8:1.
- Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 suppl):D34–41.
- 176. Fritz JS, Blair C, Oudiz RJ, et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. *Chest.* 2013;143(2):315–23.
- 177. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. *Am J Hum Genet*. 2000;67(3):737–44.
- 178. Lane KB, Machado RD, Pauciulo MW, et al. The International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. *Nat Genet.* 2000; 26(1):81–4.
- Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. *Am J Hum Genet*. 2001;68(1):92–102.
- Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. *NEngl J Med.* 2001;345(5):319–24.
- 181. Dweik RA, Rounds S, Erzurum SC, et al. ATS Committee on Pulmonary Hypertension Phenotypes. An official American Thoracic Society Statement: pulmonary hypertension phenotypes. *Am J Respir Crit Care Med.* 2014;189(3): 345–55.
- 182. Minkin R, Sandhu G, Grosu H, et al. Desmosine and isodesmosine as a novel biomarker for pulmonary arterial hypertension: a pilot study. *Am J Ther.* 2015 Jul 31. [Epub ahead of print].
- Hilgendorff A, Parai K, Ertsey R, et al. Lung matrix and vascular remodeling in mechanically ventilated elastin haploinsufficient newborn mice. *Am J Physiol Lung Cell Mol Physiol.* 2015;308(5):L464–78.
- 184. Kim YM, Haghighat L, Spiekerkoetter E, et al. Neutrophil elastase is produced by pulmonary artery smooth muscle cells and is linked to neointimal lesions. *Am J Pathol.* 2011;179(3):1560–72.
- Zaidi SH, You XM, Ciura S, Husain M, Rabinovitch M. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. *Circulation*. 2002;105(4):516–21.
- Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. *Nat Med.* 2000;6(6):698–702.
- 187. Zhu L, Wigle D, Hinek A, et al. The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin. J Clin Invest. 1994;94(3):1163–71.



- Todorovich-Hunter L, Johnson DJ, Ranger P, Keeley FW, Rabinovitch M. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline. A biochemical and ultrastructural study. *Lab Invest.* 1988;58(2):184–95.
- Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. *Am J Respir Crit Care Med.* 1995;151(5):1628–31.
- 190. Christmann RB, Hayes E, Pendergrass S, et al. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. *Arthritis Rheum.* 2011;63(6):1718–28.
- 191. Greenblatt MB, Sargent JL, Farina G, et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. *Am J Pathol.* 2012;180(3):1080–94.
- 192. Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. *PLoS One*. 2009;4(6):e5903.
- 193. Cho W, Chen N, Tang C, Elias JA, Lee C. IL-13-induces vascular remodeling and pulmonary arterial hypertension via arginase 2-dependent pathway. *Am J Respir Crit Care Med.* 2010;181:A6323.
- 194. Graham BB, Mentink-Kane MM, El-Haddad H, et al. Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. *Am J Pathol.* 2010;177(3):1549–61.
- Park SH, Chen WC, Esmaeil N, et al. IL-13 and IL-17 A induced pulmonaryhypertension-phenotype due to inhalation of antigen and fine particles from air pollution. *Pulm Circ.* 2014;4(4):654–68.
- 196. Kumar R, Mickael C, Chabon J, et al. The causal role of IL-4 and IL-13 in Schistosoma mansoni pulmonary hypertension. Am J Respir Crit Care Med. 2015;192(8):998-1008.
- 197. Voelkel NF, Tuder RM, Bridges J, Arend WP. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. *Am J Respir Cell Mol Biol.* 1994;11(6):664–75.
- Hagen M, Fagan K, Steudel W, et al. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. *Am J Physiol Lung Cell Mol Physiol*. 2007;292(6):L1473-9.
- 199. Samet JM, Dominici F, Curriero FC, Coursac I, Zeger SL. Fine particulate air pollution and mortality in 20 U.S. cities, 1987–94. N Engl J Med. 2000; 343(24):1742–9.
- Maynard RL. The effects on health of ambient particles: time for an agonizing reappraisal? *Cell Biol Toxicol.* 2015;31(3):131–47.
- Holland N, Davé V, Venkat S, et al. Ozone inhalation leads to a dose-dependent increase of cytogenetic damage in human lymphocytes. *Environ Mol Mutagen*. 2015;56(4):378–87.
- 202. Lippmann M. Environmental Toxicants: Human Exposures and Their Health Effects. 3rd ed. Hoboken, NJ: John Wiley & Sons; 2009.
- Schlesinger RB. The health impact of common inorganic components of fine particulate matter (PM2.5) in ambient air: a critical review. *Inhal Toxicol.* 2007;19(10):811-32.
- Lippmann M, Chen LC, Gordon T, Ito K, Thurston GD. National Particle Component Toxicity (NPACT) initiative: integrated epidemiologic and toxicologic studies of the health effects of particulate matter components. *Res Rep Health Eff Inst.* 2013;(177):5–13.
- Choi JK, Ban SJ, Kim YP, Kim YH, Yi SM, Zoh KD. Molecular marker characterization and source appointment of particulate matter and its organic aerosols. *Chemosphere*. 2015;134:482–91.
- Cong Z, Kawamura K, Kang S, Fu P. Penetration of biomass-burning emissions from South Asia through the Himalayas: new insights from atmospheric organic acids. *Sci Rep.* 2015;5:9580.
- 207. Cordell RL, White IR, Monks PS. Validation of an assay for the determination of levoglucosan and associated monosaccharide anhydrides for the quantification of wood smoke in atmospheric aerosol. *Anal Bioanal Chem.* 2014;406(22): 5283–92.
- Xie M, Hannigan MP, Barsanti KC. Gas/particle partitioning of 2-methyltetrols and levoglucosan at an urban site in Denver. *Environ Sci Technol.* 2014;48(5): 2835–42.
- Rao CY, Riggs MA, Chew GL, et al. Characterization of airborne molds, endotoxins, and glucans in homes in New Orleans after Hurricanes Katrina and Rita. *Appl Environ Microbiol.* 2007;73(5):1630–4.
- Voelkel NF, Mizuno S, Yasuo M. Does drug-induced emphysema exist? *Eur Respir J.* 2013;42(6):1464–8.
- Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol. 1999;104(1):5–13.
- Hargreaves MR, Benson MK. Inhaled sodium cromoglycate in angiotensinconverting enzyme inhibitor cough. *Lancet.* 1995;345(8941):13–6.
- 213. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. *N Engl J Med.* 1996;335(9):609–16.
- Yasuo M, Mizuno S, Allegood J, et al. Fenretinide causes emphysema, which is prevented by sphingosine 1-phoshate. *PLoS One*. 2013;8(1):e53927.

- Yagoda A, Mukherji B, Young C, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. *Ann Intern Med.* 1972;77(6):861–70.
- Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. *Crit Rev Toxicol*. 1992;22(5-6):307-25.
- Makellar A. An Investigation into the Nature of Black Phthisis; or Ulceration Induced by Carbonaceous Accumulation in Lungs of Coal Miners and Other Operatives. Medico-Chirurgical Society of Edinburgh; from the Scottish Mining Website; 1846.
- Scano G, Garcia-Herreros P, Stendardi D, Degre S, De Coster A, Sergysels R. Cardiopulmonary adaptation to exercise in coal miners. *Arch Environ Health*. 1980;35(6):360-6.
- Lovasi GS, Diez Roux AV, Hoffman EA, Kawut SM, Jacobs DR Jr, Barr RG. Association of environmental tobacco smoke exposure in childhood with early emphysema in adulthood among nonsmokers: the MESA-lung study. *Am J Epidemiol.* 2010;171(1):54–62.
- 220. Vineis P, Airoldi L, Veglia F, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. *Br Med J.* 2005;330(7486):277.
- Joseph AM, Hecht SS, Murphy SE, et al. Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. *Cancer Epidemiol Biomarkers Prev.* 2005;14(12):2963–8.
- 222. Marks GB, Tovey ER, Toelle BG, Wachinger S, Peat JK, Woolcock AJ. Mite allergen (Der p 1) concentration in houses and its relation to the presence and severity of asthma in a population of Sydney schoolchildren. J Allergy Clin Immunol. 1995;96(4):441–8.
- Platts-Mills TA, Sporik RB, Wheatley LM, Heymann PW. Is there a doseresponse relationship between exposure to indoor allergens and symptoms of asthma? *J Allergy Clin Immunol.* 1995;96(4):435–40.
- Fireman E, Goshen M, Ganor E, Spirer Z, Lerman Y. Induced sputum as an additional tool in the identification of metal-induced sarcoid-like reaction. *Sarcoidosis Vasc Diffuse Lung Dis.* 2004;21(2):152-6.
- Fireman E, Lerman Y, Stark M, et al. Detection of occult lung impairment in welders by induced sputum particles and breath oxidation. *Am J Ind Med.* 2008;51(7):503–11.
- 226. Fireman EM, Lerman Y, Ben Mahor M, Ganor E, Kramer MR. Redefining idiopathic interstitial lung disease into occupational lung diseases by analysis of chemical composition of inhaled dust particles in induced sputum and/or lung biopsy specimens. *Toxicol Ind Health*. 2007;23(10):607–15.
- 227. Fireman EM, Lerman Y, Ganor E, et al. Induced sputum assessment in New York City firefighters exposed to World Trade Center dust. *Environ Health Perspect.* 2004;112(15):1564–9.
- Lerman Y, Schwarz Y, Kaufman G, Ganor E, Fireman E. Case series: use of induced sputum in the evaluation of occupational lung diseases. *Arch Environ Health.* 2003;58(5):284–9.
- Rom WN, Weiden M, Garcia R, et al. Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. *Am J Respir Crit Care Med.* 2002;166(6):797–800.
- 230. Kwon S, Weiden MD, Echevarria GC, et al. Early elevation of serum MMP-3 and MMP-12 predicts protection from World Trade Center-lung injury in New York city firefighters: a nested case-control study. *PLoS One*. 2013;8(10):e76099.
- Naveed B, Weiden MD, Kwon S, et al. Metabolic syndrome biomarkers predict lung function impairment: a nested case-control study. *Am J Respir Crit Care Med.* 2012;185(4):392–9.
- Nolan A, Kwon S, Cho SJ, et al. MMP-2 and TIMP-1 predict healing of WTClung injury in New York city firefighters. *Respir Res.* 2014;15:5.
- Nolan A, Naveed B, Comfort AL, et al. Inflammatory biomarkers predict airflow obstruction after exposure to World Trade Center dust. *Chest.* 2012; 142(2):412-8.
- Weiden MD, Naveed B, Kwon S, et al. Cardiovascular biomarkers predict susceptibility to lung injury in World Trade Center dust-exposed firefighters. *Eur Respir J.* 2013;41(5):1023–30.
- Cho SJ, Nolan A, Echevarria GC, et al. Chitotriosidase is a biomarker for the resistance to World Trade Center lung injury in New York city firefighters. J Clin Immunol. 2013;33(6):1134–42.
- 236. Weiden MD, Kwon S, Caraher E, et al. Biomarkers of World Trade Center particulate matter exposure: physiology of distal airway and blood biomarkers that predict FEV(1) decline. *Semin Respir Crit Care Med.* 2015;36(3):323–33.
- 237. Berger KI, Reibman J, Oppenheimer BW, Vlahos I, Harrison D, Goldring RM. Lessons from the World Trade Center disaster: airway disease presenting as restrictive dysfunction. *Chest.* 2013;144(1):249–57.
- 238. Kazeros A, Maa MT, Patrawalla P, et al. Elevated peripheral eosinophils are associated with new-onset and persistent wheeze and airflow obstruction in world trade center-exposed individuals. *J Asthma*. 2013;50(1):25–32.
- Kazeros A, Zhang E, Cheng X, et al. Systemic inflammation associated with world trade center dust exposures and airway abnormalities in the local community. J Occup Environ Med. 2015;57(6):610–6.
- Polikepahad S, Knight JM, Naghavi AO, et al. Proinflammatory role for let-7 microRNAs in experimental asthma. J Biol Chem. 2010;285(39):30139–49.

- Steiner DF, Thomas MF, Hu JK, et al. MicroRNA-29 regulates T-box transcription factors and interferon-gamma production in helper T cells. *Immunity*. 2011;35(2):169–81.
- 242. Williams AE, Larner-Svensson H, Perry MM, et al. MicroRNA expression profiling in mild asthmatic human airways and effect of corticosteroid therapy. *PLoS One*. 2009;4(6):e5889.
- Biton M, Levin A, Slyper M, et al. Epithelial microRNAs regulate gut mucosal immunity via epithelium-T cell crosstalk. *Nat Immunol.* 2011;12(3):239–46.
- Lu TX, Lim EJ, Wen T, et al. MiR-375 is downregulated in epithelial cells after IL-13 stimulation and regulates an IL-13-induced epithelial transcriptome. *Mucosal Immunol.* 2012;5(4):388–96.
- Mizuno S, Bogaard HJ, Gomez-Arroyo J, et al. MicroRNA-199a-5p is associated with hypoxia-inducible factor-1alpha expression in lungs from patients with COPD. *Chest.* 2012;142(3):663–72.
- Molina-Pinelo S, Suárez R, Pastor MD, et al. Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. *Dis Markers*. 2012;32(4):221–30.
- Lewis A, Riddoch-Contreras J, Natanek SA, et al. Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. *Thorax*. 2012;67(1):26–34.
- Bockmeyer CL, Maegel L, Janciauskiene S, et al. Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. *J Heart Lung Transplant*. 2012;31(7):764–72.
- Caruso P, MacLean MR, Khanin R, et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. *Arterioscler Thromb Vasc Biol.* 2010;30(4):716–23.
- 250. Sarkar J, Gou D, Turaka P, Viktorova E, Ramchandran R, Raj JU. MicroR-NA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. *Am J Physiol Lung Cell Mol Physiol*. 2010;299(6): L861–71.
- Yang S, Banerjee S, Freitas AD, et al. miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling. *Am J Physiol Lung Cell Mol Physiol*. 2012;302(6):L521-9.
- 252. Brock M, Samillan VJ, Trenkmann M, et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. *Eur Heart J.* 2012.
- Hale AE, White K, Chan SY. Hypoxamirs in pulmonary hypertension: breathing new life into pulmonary vascular research. *Cardiovasc Diagn Ther.* 2012;2(3):200-12.
- Parikh VN, Jin RC, Rabello S, et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. *Circulation*. 2012;125(12):1520–32.
- 255. Pullamsetti SS, Doebele C, Fischer A, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. *Am J Respir Crit Care Med.* 2012;185(4):409–19.
- Courboulin A, Paulin R, Giguère NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208(3):535–48.
- Breyer MK, Rutten EP, Locantore NW, Watkins ML, Miller BE, Wouters EF. Dysregulated adipokine metabolism in chronic obstructive pulmonary disease. *Eur J Clin Invest.* 2012;42(9):983–91.
- Lavoie KL, Bacon SL, Labrecque M, Cartier A, Ditto B. Higher BMI is associated with worse asthma control and quality of life but not asthma severity. *Respir Med.* 2006;100(4):648–57.
- Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res. 2002;10(S12):97S-104S.
- Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metab. 2004;89(6):2526–39.
- 261. Schleinitz D, Klöting N, Böttcher Y, et al. Genetic and evolutionary analyses of the human bone morphogenetic protein receptor 2 (BMPR2) in the pathophysiology of obesity. *PLoS One*. 2011;6(2):e16155.
- 262. Hemnes AR, Brittain EL, Trammell AW, et al. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. *Am J Respir Crit Care Med.* 2014;189(3):325–34.
- West J, Niswender KD, Johnson JA, et al. A potential role for insulin resistance in experimental pulmonary hypertension. *Eur Respir J.* 2013;41(4):861–71.
- 264. Talati M, Hemnes A. Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy. *Pulm Circ.* 2015; 5(2):269–78.
- 265. Ryan JJ, Archer SL. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension. *Circulation*. 2015;131(19):1691–702.
- Lundgrin EL, Park MM, Sharp J, et al. Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. *Ann Am Thorac Soc.* 2013;10(1):1–9.
- 267. Graham BB, Kumar R, Mickael C, et al. Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake. *Am J Physiol Lung Cell Mol Physiol.* 2015;309(5):L435–40.

- Goncharov DA, Kudryashova TV, Ziai H, et al. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension. *Circulation*. 2014;129(8):864–74.
- 269. Cheng DT, Kim DK, Cockayne DA, et al; TESRA and ECLIPSE Investigators. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2013;188(8): 948–57.
- Sukkar MB, Wood LG, Tooze M, et al. Soluble RAGE is deficient in neutrophilic asthma and COPD. *Eur Respir J.* 2012;39(3):721–9.
- Ullah MA, Loh Z, Gan WJ, et al. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation. *J Allergy Clin Immunol.* 2014;134(2):440–50.
- 272. Berg I, Hanson C, Sayles H, et al. Vitamin D, vitamin D binding protein, lung function and structure in COPD. *Respir Med.* 2013;107(10):1578–88.
- 273. Brehm JM, Schuemann B, Fuhlbrigge AL, et al. Childhood Asthma Management Program Research Group. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program Study. J Allergy Clin Immunol. 2010;126(1):52.e5–8.e5.
- 274. Castro M, King TS, Kunselman SJ, et al. National Heart, Lung, and Blood Institute's AsthmaNet. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. J Am Med Assoc. 2014;311(20):2083–91.
- de Groot JC, van Roon EN, Storm H, et al. Vitamin D reduces eosinophilic airway inflammation in nonatopic asthma. *J Allergy Clin Immunol.* 2015;135(3): 670.e3–5.e3.
- 276. Röpcke S, Holz O, Lauer G, et al. Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. *PLoS One*. 2012;7(10):e46207.
- Hoogerwerf JJ, de Vos AF, Levi M, et al. Activation of coagulation and inhibition of fibrinolysis in the human lung on bronchial instillation of lipoteichoic acid and lipopolysaccharide. *Crit Care Med.* 2009;37(2):619–25.
- 278. van der Poll T. Tissue factor as an initiator of coagulation and inflammation in the lung. *Crit Care*. 2008;12(suppl 6):S3.
- 279. Isada A, Konno S, Hizawa N, et al. A functional polymorphism (-603 A  $\rightarrow$  G) in the tissue factor gene promoter is associated with adult-onset asthma. *J Hum Genet.* 2010;55(3):167–74.
- Park JA, Sharif AS, Tschumperlin DJ, et al. Tissue factor-bearing exosome secretion from human mechanically stimulated bronchial epithelial cells in vitro and in vivo. *J Allergy Clin Immunol.* 2012;130(6):1375–83.
- 281. Majoor CJ, van de Pol MA, Kamphuisen PW, et al. Evaluation of coagulation activation after rhinovirus infection in patients with asthma and healthy control subjects: an observational study. *Respir Res.* 2014;15:14.
- Welsh CH. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. *Chest.* 1996;110(3):710.
- Bonderman D, Turecek PL, Jakowitsch J, et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. *Thromb Haemost*. 2003;90(3):372–6.
- 284. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMP-ERA). *Circulation*. 2014;129(1):57–65.
- Opitz CF, Kirch W, Mueller EA, Pittrow D. Bleeding events in pulmonary arterial hypertension. *Eur J Clin Invest*. 2009;39(suppl 2):68–73.
- Cui L, Morris A, Huang L, et al. The microbiome and the lung. Ann Am Thorac Soc. 2014;11(suppl 4):S227–32.
- Segal LN, Blaser MJ. A brave new world: the lung microbiota in an era of change. Ann Am Thorac Soc. 2014;11(suppl 1):S21–7.
- Reibman J, Marmor M, Filner J, et al. Asthma is inversely associated with Helicobacter pylori status in an urban population. *PLoS One*. 2008;3(12):e4060.
- 289. Liu B, Faller LL, Klitgord N, et al. Deep sequencing of the oral microbiome reveals signatures of periodontal disease. *PLoS One*. 2012;7(6):e37919.
- 290. Wu GD, Lewis JD, Hoffmann C, et al. Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. *BMC Microbiol.* 2010;10(1):206.
- Segal LN, Rom WN, Weiden MD. Lung microbiome for clinicians. New discoveries about bugs in healthy and diseased lungs. *Ann Am Thorac Soc.* 2014;11(1):108-16.
- 292. Segal LN, Alekseyenko AV, Clemente JC, et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. *Microbiome*. 2013;1(1):19.
- Calışkan M, Bochkov YA, Kreiner-Møller E, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. N Engl J Med. 2013;368(15): 1398–407.
- 294. Voraphani N, Stern DA, Wright AL, Guerra S, Morgan WJ, Martinez FD. Risk of current asthma among adult smokers with respiratory syncytial virus illnesses in early life. *Am J Respir Crit Care Med.* 2014;190(4):392–8.



- Rakes GP, Arruda E, Ingram JM, et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. *Am J Respir Crit Care Med.* 1999;159(3):785–90.
- Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. Br Med J. 1993;307(6910):982-6.
- 297. Huang YJ, Nelson CE, Brodie EL, et al. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. *J Allergy Clin Immunol.* 2011;127(2): 372.e1-3–81.e1-3.
- 298. Ost DE, Ernst A, Lei X, et al. AQuIRE Bronchoscopy Registry. Diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration: results of the AQuIRE Bronchoscopy Registry. *Chest.* 2011;140(6):1557–66.
- Saunders CAB, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. *Ann Thorac Surg.* 1999;67(3):790–7.
- 300. Cho MH, Castaldi PJ, Hersh CP, et al. NETT Genetics, ECLIPSE, and COPDGene Investigators. A Genome-Wide Association Study of emphysema and airway quantitative imaging phenotypes. *Am J Respir Crit Care Med.* 2015;192(5):559-69.
- Washko GR. Imaging to predict therapeutic outcomes. Am J Respir Crit Care Med. 2015;191(7):724–5.
- 302. Wells JM, Iyer AS, Rahaghi FN, et al. Pulmonary artery enlargement is associated with right ventricular dysfunction and loss of blood volume in small pulmonary vessels in chronic obstructive pulmonary disease. *Circ Cardiovasc Imaging*. 2015 Apr;8(4). pii: e002546. doi: 10.1161/CIRCIMAGING.114.002546.

- 303. Hoffman EA, Lynch DA, Barr RG, van Beek EJ, Parraga G, Investigators I. Pulmonary CT and MRI phenotypes that help explain chronic pulmonary obstruction disease pathophysiology and outcomes. *J Magn Reson Imaging*. 2015 Jul 22. doi: 10.1002/jmri.25010. [Epub ahead of print].
- Brenner DJ, Hall EJ. Computed tomography an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277–84.
- Hricak H, Brenner DJ, Adelstein SJ, et al. Managing radiation use in medical imaging: a multifaceted challenge. *Radiology*. 2011;258(3):889–905.
- Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology: the impact of new epidemiological data. *Br J Radiol.* 2012;85(1020):e1316–7.
- Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. *Thorax*. 2015;70(8):748–56.
- Grunig G, Corry DB, Reibman J, Wills-Karp M. Interleukin 13 and the evolution of asthma therapy. *Am J Clin Exp Immunol.* 2012;1(1):20–7.
- Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 suppl):D60-72.
- Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 suppl):D42-50.
- Woodhouse N, Wild JM, Paley MN, et al. Combined helium-3/proton magnetic resonance imaging measurement of ventilated lung volumes in smokers compared to never-smokers. *J Magn Reson Imaging*. 2005;21(4):365–9.